Maxillary sinus diseases – diagnosis and differential diagnosis

Petkova, Milena; Deliverska, Elitza

doi:10.18044/medinform.201632.450

Search citation statements

Order By: Relevance

Paper Sections

Select...

Rituximab For Multiple Myeloma (Mm)1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Open Journal of Blood Diseases order to effectively attack multiple myeloma cells with rituximab [35]. The experimental results of Li Juan et al show that when the concentration is greater than 100 ug/ml [36]. Thalidomide combined with 16 ug/mI.…”

Section: Rituximab For Multiple Myeloma (Mm)mentioning

confidence: 99%

Progress in the Treatment of Hematological Diseases with Rituximab

Fu¹,

Lin²,

Yao³

et al. 2021

OJBD

View full text Add to dashboard Cite

Rituximab is a mouse and human chimeric CD 20 (anti-B cell) specific monoclonal antibody that has been approved by the U.S. Food and Drug Administration for the treatment of lymphoma. The expression of CD 20 antigen is expressed in the whole ontogeny of B cells, starting from the premature B cells in bone marrow to the differentiation of plasma cells in secondary lymphoid tissues. The wide distribution of CD 20 molecules allows rituximab to eliminate a large number of B cells. Rituximab is the core drug for the treatment of hematological diseases, often combined with drugs as a first-line treatment. Long-term hormone therapy often results in serious adverse reactions, and new therapies, which can avoid widespread immunotoxicity, have great potential for treating diseases of the blood system.

show abstract

Section: Rituximab For Multiple Myeloma (Mm)mentioning

confidence: 99%